Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ABP OTCMKTS:AOXG NASDAQ:BCLI NASDAQ:EQ On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABPAbpro$0.21+7.0%$0.22$0.15▼$13.00$12.66MN/A5.48 million shs2.92 million shsAOXGAoxing Pharmaceutical$0.01-6.7%$0.01$0.00▼$0.02$2.67M6.7389,282 shs1,800 shsBCLIBrainstorm Cell Therapeutics$1.21-0.8%$1.18$0.72▼$6.45$11.91M0.22398,974 shs186,450 shsEQEquillium$0.35+1.4%$0.36$0.27▼$1.50$12.61M1.86749,256 shs172,170 shsA Beginner's Guide to Investing in CannabisUnlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABPAbpro-4.09%+3.56%-28.68%-29.46%+19,469,900.00%AOXGAoxing Pharmaceutical0.00%0.00%0.00%-6.25%-20.21%BCLIBrainstorm Cell Therapeutics-1.61%+7.02%-2.40%+60.02%-76.83%EQEquillium+3.29%+6.48%-0.68%-27.31%-52.43%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationABPAbproN/AN/AN/AN/AN/AN/AN/AN/AAOXGAoxing PharmaceuticalN/AN/AN/AN/AN/AN/AN/AN/ABCLIBrainstorm Cell Therapeutics2.1615 of 5 stars0.04.00.04.72.40.80.6EQEquillium1.8721 of 5 stars3.22.00.00.01.11.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABPAbpro 3.00Buy$4.001,820.31% UpsideAOXGAoxing Pharmaceutical 0.00N/AN/AN/ABCLIBrainstorm Cell Therapeutics 0.00N/AN/AN/AEQEquillium 2.33Hold$3.00749.86% UpsideCurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABPAbpro$183K69.19N/AN/A($0.29) per share-0.72AOXGAoxing PharmaceuticalN/AN/AN/AN/AN/AN/ABCLIBrainstorm Cell TherapeuticsN/AN/AN/AN/A($1.36) per shareN/AEQEquillium$41.10M0.31N/AN/A$0.54 per share0.65Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABPAbpro-$7.23MN/A0.00∞N/AN/AN/A-198.95%N/AAOXGAoxing PharmaceuticalN/AN/A0.00∞N/AN/AN/AN/AN/ABCLIBrainstorm Cell Therapeutics-$11.62M-$3.36N/AN/AN/AN/AN/A-519.50%8/13/2025 (Estimated)EQEquillium-$8.07M-$0.39N/AN/AN/A-19.62%-74.34%-46.75%8/6/2025 (Estimated)Latest AOXG, EQ, ABP, and BCLI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/6/2025Q1 2025EQEquillium-$0.1850N/AN/AN/AN/AN/A5/15/2025N/AABPAbproN/A-$0.08N/A-$0.08N/AN/A5/15/2025Q1 2025BCLIBrainstorm Cell Therapeutics-$0.38-$0.45-$0.07-$0.45N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthABPAbproN/AN/AN/AN/AN/AAOXGAoxing PharmaceuticalN/AN/AN/AN/AN/ABCLIBrainstorm Cell TherapeuticsN/AN/AN/AN/AN/AEQEquilliumN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABPAbproN/A0.110.11AOXGAoxing PharmaceuticalN/AN/AN/ABCLIBrainstorm Cell TherapeuticsN/A0.210.21EQEquilliumN/A2.702.70Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABPAbpro23.30%AOXGAoxing PharmaceuticalN/ABCLIBrainstorm Cell Therapeutics14.33%EQEquillium27.05%Insider OwnershipCompanyInsider OwnershipABPAbpro20.80%AOXGAoxing Pharmaceutical17.80%BCLIBrainstorm Cell Therapeutics11.15%EQEquillium31.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABPAbpro1560.79 million48.14 millionN/AAOXGAoxing Pharmaceutical350381.21 million313.35 millionNot OptionableBCLIBrainstorm Cell Therapeutics409.84 million8.74 millionOptionableEQEquillium4035.72 million24.43 millionNot OptionableAOXG, EQ, ABP, and BCLI HeadlinesRecent News About These CompaniesInterleukin-2 Inhibitors Clinical Trial Pipeline Accelerates as 20+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight4 hours ago | finance.yahoo.comEquillium, Inc. (EQ) stock price, news, quote & history - Yahoo FinanceJune 26, 2025 | nz.finance.yahoo.com4 Emerging Graft versus Host Disease Therapies That Could Change the Treatment Landscape | DelveInsightJune 14, 2025 | medindia.netMEquillium expands equity incentive plan by 1.78 million sharesMay 24, 2025 | investing.comEquillium Announces Multiple Poster Presentations Highlighting EQ504 at the Annual Meeting of The American Association of ImmunologistsMay 6, 2025 | finance.yahoo.comEquillium advancing new AhR modulatorMay 3, 2025 | bioworld.comBEquillium Announces New Aryl Hydrocarbon Receptor Modulator Program EQ504May 1, 2025 | finance.yahoo.comBlood Cancer Data Ignore Sex; Cancer Biosimilars Take Off; Mixed Prevention NewsApril 26, 2025 | msn.comEquillium says FDA declines Breakthrough Therapy designation for itolizumabApril 25, 2025 | markets.businessinsider.comLeerink says Equillium’s itolizumab news ‘disappointing but not surprising’April 25, 2025 | markets.businessinsider.comFDA declines itolizumab accelerated approval, says EquilliumApril 25, 2025 | thepharmaletter.comTEquillium shares fall following FDA feedbackApril 24, 2025 | in.investing.comEquillium Announces Feedback from the U.S. Food and Drug AdministrationApril 24, 2025 | finance.yahoo.comEquillium (EQ) May Find a Bottom Soon, Here's Why You Should Buy the Stock NowApril 1, 2025 | zacks.comThe week in pharma: action, reaction and insight – week to March 28March 30, 2025 | thepharmaletter.comTEquillium downgraded to Market Perform from Outperform at LeerinkMarch 29, 2025 | markets.businessinsider.comEquillium reports Q4 EPS (16c) vs. (7c) last yearMarch 28, 2025 | markets.businessinsider.comEquillium reports EQUATOR study did not improve complete, overall response ratesMarch 28, 2025 | markets.businessinsider.comEquillium Full Year 2024 Earnings: Beats ExpectationsMarch 28, 2025 | finance.yahoo.comEquillium says graft-versus-host drug fails Phase 3, stock divesMarch 27, 2025 | endpts.comENew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWhy BigBear.ai Could Rally 100% and Catch Palantir SoonBy Gabriel Osorio-Mazilli | June 30, 2025View Why BigBear.ai Could Rally 100% and Catch Palantir Soon3 Defense Leaders Set to Gain From Rising Military SpendBy Chris Markoch | July 5, 2025View 3 Defense Leaders Set to Gain From Rising Military SpendIPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBy Dan Schmidt | June 20, 2025View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeAI Chip Arms Race: 3 Must-Watch Equipment StocksBy Chris Markoch | July 10, 2025View AI Chip Arms Race: 3 Must-Watch Equipment StocksCorrection Equals Opportunity in Domino’s Pizza StockBy Gabriel Osorio-Mazilli | July 6, 2025View Correction Equals Opportunity in Domino’s Pizza StockAOXG, EQ, ABP, and BCLI Company DescriptionsAbpro NASDAQ:ABP$0.21 +0.01 (+6.99%) As of 02:21 PM EasternAbpro Holdings Inc. is a biotechnology company. The company's mission is to improve the lives of mankind facing severe and life-threatening diseases with next-generation antibody therapies. Abpro Holdings Inc., formerly known as Atlantic Coastal Acquisition Corp. II, is based in WOBURN, Mass.Aoxing Pharmaceutical OTCMKTS:AOXG$0.0070 0.00 (-6.67%) As of 12:08 PM EasternAoxing Pharmaceutical Company, Inc. a specialty pharmaceutical company, engages in research and development, manufacture, and distribution of narcotic, pain-management, and addiction treatment pharmaceutical products primarily in the People's Republic of China. The company's principal products include Zhongtong'an, a capsule of herbal extraction for the indication of oral and dental pain; and Yiqi Qiangshen Granule, an OTC herbal extraction for tonifying qi and empowering body, and promoting blood circulation to remove meridian obstruction, as well as Tilidine hydrochloride, an orally-absorbed synthetic narcotic analgesic tablet used in 50mg or 100mg dosage for relief of acute, moderate to severe pain, and chronic cancer-related pain. Its products under development comprise Oxycodone and Acetaminophen tablets and capsules, which has completed clinical trials for the treatment of acute and chronic pain; Buprenorphine/Naloxone, a sublingual combo tablet that has completed Phase II clinical trials for the treatment of opioid dependence; and Tilidine/Naloxone, a compound capsule which is in Phase II clinical trial to treat acute and chronic pain. The company was formerly known as China Aoxing Pharmaceutical Company, Inc. and changed its name to Aoxing Pharmaceutical Company, Inc. in March 2010. Aoxing Pharmaceutical Company, Inc. is headquartered in Shijiazhuang, China.Brainstorm Cell Therapeutics NASDAQ:BCLI$1.21 -0.01 (-0.82%) As of 02:38 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is developing NurOwn, which has completed Phase III clinical trial for the treatment of amyotrophic lateral sclerosis; Phase II clinical trial for the treatment of progressive multiple sclerosis; and for the treatment of alzheimer's disease, as well as for other neurodegenerative diseases. Brainstorm Cell Therapeutics Inc. was incorporated in 2000 and is headquartered in New York, New York.Equillium NASDAQ:EQ$0.35 +0.00 (+1.38%) As of 02:38 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a first-in-class monoclonal antibody that targets the immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase I clinical trial for the treatment of ulcerative colitis; and Phase I clinical trial for the treatment of lupus nephritis. It also develops EQ101 completed phase 1/2 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ302 to treat gastrointestinal indications. In addition, it serves dermatology, gastroenterology, rheumatology, hematology, transplant science, oncology, and pulmonology area. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Super Micro Computer: The Hidden Winner of Soaring Copper Tariffs Nebius Group: Up 385%, Analysts Say It’s Still a Bargain Broadcom Stock: HSBC Sets $400 Target on AI Growth Potential BigBear.ai: Why a 90% Rally Could Be Just the Start Chipotle: Too Spicy for Smart Money to Resist After Stock Split Plug Power’s 20% Surge Signals New Commercial Growth Era Will Oracle's Cloud and AI Deals Propel It to New Highs? Enovix Shares Hit 6-Month High; Long-Term Highs to Follow Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
